查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1472356

左旋多巴市场：按形式、给药途径和分销管道分类：2023-2032 年全球机会分析和产业预测

Levodopa Market By Form, By Route of Administration, By Distribution Channels : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 300 Pages | 商品交期: 2-3个工作天内

价格

预计到 2032 年，全球左旋多巴市场将从 2022 年的 16.554 亿美元成长至 29.346 亿美元，2023 年至 2032 年的复合年增长率为 6.1%。

左旋多巴市场-IMG1

左旋多巴，通常称为左旋多巴，是一种在体内转化为多巴胺的化学成分。多巴胺是大脑分泌的化学信使。多巴胺促进快乐、大脑功能和记忆过程。几乎所有患者都接受左旋多巴治疗，左旋多巴是一种多巴胺前体，可有效控制帕金森氏症 (PD) 的早期症状。碳度巴通常与含左旋多巴的药物合併使用，透过减少多巴胺的代谢来提高其疗效。

由于医疗保健基础设施投资增加、可支配收入增加以及新兴市场获得医疗保健的机会迅速增加，左旋多巴市场正在经历显着增长。此外，随着新兴国家加强医疗保健系统，用于治疗帕金森氏症的左旋多巴等药物的供应和价格正在增加。医疗保健服务的改善将提高诊断和治疗的起始率，从而推动对左旋多巴的需求。此外，可支配收入的增加使个人能够负担得起基本药物，从而促进市场成长。此外，这些因素的结合不仅扩大了患者基础，也为左旋多巴市场的製药公司创造了新的成长机会，特别是在医疗基础设施发达的地区。然而，与左旋多巴相关的高成本是限制左旋多巴市场成长的主要因素之一。此外，它还限制了患者获得这种治疗帕金森氏症的重要药物，特别是在医疗保健资源有限和低收入人群的地区。此外，左旋多巴的经济问题阻碍患者寻求一致的治疗或遵守规定的治疗方案，导致疾病管理结果不佳。此外，高成本可能导致医疗保健预算紧张，限制报销选择，并抑制市场成长。此外，解决负担能力障碍对于确保公平获得左旋多巴并减轻对市场成长和患者照护的影响至关重要。

相反，药物输送系统的技术进步有望透过创新配方和替代给药途径提高左旋多巴疗效和患者依从性，并有望推动市场成长。此外，医疗保健支出的增加，特别是在新兴地区，增加了左旋多巴的可及性并推动市场成长。此外，新兴市场加上人口老化，为市场渗透提供了开拓的潜力。此外，探索新配方和联合治疗的持续研究计划和通路开发正在增强左旋多巴的市场前景。此外，支持性医疗保健政策和报销框架确保了广泛的可及性，提高的疾病意识和诊断率有助于市场成长。

相关人员的主要利益

  • 本报告定量分析了 2022 年至 2032 年左旋多巴市场分析的细分市场、当前趋势、估计/趋势和动态，并确定了左旋多巴市场的强大机会。
  • 我们提供市场研究以及与市场驱动因素、市场限制和市场机会相关的资讯。
  • 波特的五力分析强调买家和供应商帮助相关人员做出利润驱动的商业决策并加强供应商-买家网路的力量。
  • 详细分析左旋多巴市场细分将有助于确定市场机会。
  • 每个地区的主要国家都根据其对全球市场的收益贡献绘製了地图。
  • 市场参与者定位有助于基准化分析，并提供对市场参与者当前位置的清晰了解。
  • 该报告包括对区域和全球左旋多巴市场趋势、主要企业、细分市场、应用领域和市场成长策略的分析。

此报告可进行客製化（需要额外费用和时间表）

  • 产品中所含原料分析（按百分比）
  • 投资机会
  • 科技趋势分析
  • 按产品/细分市场分類的参与者市场区隔分析
  • 新产品开发/主要厂商产品矩阵
  • 监管指引
  • 根据客户兴趣新增其他公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 十字交叉细分市场分析 - 市场规模与预测
  • 公司简介的扩充列表
  • 历史市场资料
  • 主要参与者的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）
  • 客户/消费者/原料供应商名单 - 价值链分析
  • 全球/区域/国家层级参与者的市场占有率分析

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
  • 平均售价
  • 市场占有率分析
  • 品牌占有率分析
  • 贸易资料分析
  • 产品消费
  • 价值链分析
  • 监管指引
  • 关键监管分析
  • 赎回场景
  • 专利状况

第四章 左旋多巴市场：依形式

  • 概述
  • 锭剂
  • 胶囊
  • 粉末
  • 液体

第五章 左旋多巴市场：依途径

  • 概述
  • 口服
  • 胃肠外的

第六章 左旋多巴市场：依通路

  • 概述
  • 医院药房
  • 零售药房
  • 网路药房
  • 其他的

第七章 左旋多巴市场：依地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 其他的
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 其他的
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 其他的

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 有竞争力的仪表板
  • 竞争热图
  • 2022年主要企业定位

第九章 公司简介

  • Novartis AG
  • Merck and Co. Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Co.
  • Teva Pharmaceutical Industries Ltd.
  • Impax Laboratories Inc.
  • Pfizer Inc.
  • UCB SA
  • Sun Pharmaceutical Industries Ltd.
  • Mylan Nv
Product Code: A213646

The global levodopa market is anticipated to reach $2,934.6 million by 2032, growing from $1,655.4 million in 2022 at a CAGR of 6.1% from 2023 to 2032.

Levodopa Market - IMG1

Levodopa, commonly called L-Dopa, is a chemical building block converted into dopamine in the body. Dopamine is a chemical messenger secreted in the brain. It facilitates pleasure, brain function, and memory processes. Almost all patients get levodopa, a dopamine precursor that effectively controls Parkinson's disease (PD) symptoms in its early stages. Carbidopa is frequently used in combination with levodopa-containing medications to increase their efficacy by decreasing dopamine metabolism.

The levodopa market has been witnessing significant growth, owing to rise in investments in healthcare infrastructure, increase in disposable income, and surge in healthcare access in emerging markets. Moreover, as emerging economies bolster their healthcare systems, increase in availability and affordability of medications such as levodopa for Parkinson's disease management. Improved access to healthcare services translates into greater diagnosis rates and treatment initiation, consequently driving the demand for levodopa. Furthermore, increase in disposable income empowers individuals to afford essential medications, driving the market growth. In addition, the combination of these factors not only expands the patient pool but also creates new growth opportunities for pharmaceutical companies operating in the levodopa market, particularly in regions with evolving healthcare infrastructures. However, high cost associated with levodopa is one of the key factors restraining the growth of the levodopa market. Moreover, affordability issues limit patient access to this crucial medication for Parkinson's disease management, particularly in regions with limited healthcare resources and low-income populations. Furthermore, the financial problem of levodopa prevents patients from seeking consistent treatment or adhering to prescribed regimens, leading to suboptimal disease management outcomes. In addition, the high cost may strain healthcare budgets and limit reimbursement options, restraining market growth. Moreover, addressing the affordability barrier is imperative to ensure equitable access to levodopa and mitigate its impact on market growth and patient care.

On the contrary, increase in technological advancements in drug delivery systems promise to enhance levodopa's efficacy and patient adherence through innovative formulations and alternative administration routes are expected to drive the market growth. Furthermore, rise in healthcare expenditure, especially in developing regions, facilitates greater accessibility to levodopa, driving the market growth. In addition, emerging markets, coupled with increase in geriatric population, offer untapped potential for market penetration. Moreover, ongoing research initiatives and channel developments exploring novel formulations and combination therapies bolster levodopa's market prospects. Furthermore, supportive healthcare policies and reimbursement frameworks ensure widespread accessibility, while increase in disease awareness and diagnosis rates contribute to the market growth.

The key players operating in the levodopa market include Novartis AG, Merck & Co. Inc., Eli Lilly & Company, Bristol-Myers Squibb Co., Teva Pharmaceutical Industries Ltd., Impax Laboratories Inc., Pfizer Inc., UCB SA, Sun Pharmaceutical Industries Ltd., and Mylan NV. In addition, the market players are increasingly focusing on adopting strategies such as collaborations and acquisitions to gain a competitive edge in the market.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the levodopa market analysis from 2022 to 2032 to identify the prevailing levodopa market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the levodopa market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global levodopa market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Analysis of raw material in a product (by %)
  • Investment Opportunities
  • Technology Trend Analysis
  • Market share analysis of players by products/segments
  • New Product Development/ Product Matrix of Key Players
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • List of customers/consumers/raw material suppliers- value chain analysis
  • Market share analysis of players at global/region/country level

Key Market Segments

By Form

  • Tablets
  • Capsules
  • Powder
  • Liquid

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • United Arab Emirates
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Novartis AG
    • Merck and Co. Inc.
    • Eli Lilly and Company
    • Bristol-Myers Squibb Co.
    • Teva Pharmaceutical Industries Ltd.
    • Impax Laboratories Inc.
    • Pfizer Inc.
    • UCB SA
    • Sun Pharmaceutical Industries Ltd.
    • Mylan Nv

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities
  • 3.5. Average Selling Price
  • 3.6. Market Share Analysis
  • 3.7. Brand Share Analysis
  • 3.8. Trade Data Analysis
  • 3.9. Product Consumption
  • 3.10. Value Chain Analysis
  • 3.11. Regulatory Guidelines
  • 3.12. Key Regulation Analysis
  • 3.13. Reimbursement Scenario
  • 3.14. Patent Landscape

CHAPTER 4: LEVODOPA MARKET, BY FORM

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Tablets
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Capsules
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Powder
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Liquid
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oral
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Parenteral
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: LEVODOPA MARKET, BY DISTRIBUTION CHANNELS

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Pharmacies
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Other
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country

CHAPTER 7: LEVODOPA MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Form
    • 7.2.3. Market size and forecast, by Route of Administration
    • 7.2.4. Market size and forecast, by Distribution Channels
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Form
      • 7.2.5.1.2. Market size and forecast, by Route of Administration
      • 7.2.5.1.3. Market size and forecast, by Distribution Channels
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Form
      • 7.2.5.2.2. Market size and forecast, by Route of Administration
      • 7.2.5.2.3. Market size and forecast, by Distribution Channels
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Form
      • 7.2.5.3.2. Market size and forecast, by Route of Administration
      • 7.2.5.3.3. Market size and forecast, by Distribution Channels
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Form
    • 7.3.3. Market size and forecast, by Route of Administration
    • 7.3.4. Market size and forecast, by Distribution Channels
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Form
      • 7.3.5.1.2. Market size and forecast, by Route of Administration
      • 7.3.5.1.3. Market size and forecast, by Distribution Channels
      • 7.3.5.2. UK
      • 7.3.5.2.1. Market size and forecast, by Form
      • 7.3.5.2.2. Market size and forecast, by Route of Administration
      • 7.3.5.2.3. Market size and forecast, by Distribution Channels
      • 7.3.5.3. France
      • 7.3.5.3.1. Market size and forecast, by Form
      • 7.3.5.3.2. Market size and forecast, by Route of Administration
      • 7.3.5.3.3. Market size and forecast, by Distribution Channels
      • 7.3.5.4. Spain
      • 7.3.5.4.1. Market size and forecast, by Form
      • 7.3.5.4.2. Market size and forecast, by Route of Administration
      • 7.3.5.4.3. Market size and forecast, by Distribution Channels
      • 7.3.5.5. Italy
      • 7.3.5.5.1. Market size and forecast, by Form
      • 7.3.5.5.2. Market size and forecast, by Route of Administration
      • 7.3.5.5.3. Market size and forecast, by Distribution Channels
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Form
      • 7.3.5.6.2. Market size and forecast, by Route of Administration
      • 7.3.5.6.3. Market size and forecast, by Distribution Channels
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Form
    • 7.4.3. Market size and forecast, by Route of Administration
    • 7.4.4. Market size and forecast, by Distribution Channels
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. China
      • 7.4.5.1.1. Market size and forecast, by Form
      • 7.4.5.1.2. Market size and forecast, by Route of Administration
      • 7.4.5.1.3. Market size and forecast, by Distribution Channels
      • 7.4.5.2. Japan
      • 7.4.5.2.1. Market size and forecast, by Form
      • 7.4.5.2.2. Market size and forecast, by Route of Administration
      • 7.4.5.2.3. Market size and forecast, by Distribution Channels
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Form
      • 7.4.5.3.2. Market size and forecast, by Route of Administration
      • 7.4.5.3.3. Market size and forecast, by Distribution Channels
      • 7.4.5.4. South Korea
      • 7.4.5.4.1. Market size and forecast, by Form
      • 7.4.5.4.2. Market size and forecast, by Route of Administration
      • 7.4.5.4.3. Market size and forecast, by Distribution Channels
      • 7.4.5.5. Australia
      • 7.4.5.5.1. Market size and forecast, by Form
      • 7.4.5.5.2. Market size and forecast, by Route of Administration
      • 7.4.5.5.3. Market size and forecast, by Distribution Channels
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Form
      • 7.4.5.6.2. Market size and forecast, by Route of Administration
      • 7.4.5.6.3. Market size and forecast, by Distribution Channels
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Form
    • 7.5.3. Market size and forecast, by Route of Administration
    • 7.5.4. Market size and forecast, by Distribution Channels
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Form
      • 7.5.5.1.2. Market size and forecast, by Route of Administration
      • 7.5.5.1.3. Market size and forecast, by Distribution Channels
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Form
      • 7.5.5.2.2. Market size and forecast, by Route of Administration
      • 7.5.5.2.3. Market size and forecast, by Distribution Channels
      • 7.5.5.3. United Arab Emirates
      • 7.5.5.3.1. Market size and forecast, by Form
      • 7.5.5.3.2. Market size and forecast, by Route of Administration
      • 7.5.5.3.3. Market size and forecast, by Distribution Channels
      • 7.5.5.4. South Africa
      • 7.5.5.4.1. Market size and forecast, by Form
      • 7.5.5.4.2. Market size and forecast, by Route of Administration
      • 7.5.5.4.3. Market size and forecast, by Distribution Channels
      • 7.5.5.5. Rest of LAMEA
      • 7.5.5.5.1. Market size and forecast, by Form
      • 7.5.5.5.2. Market size and forecast, by Route of Administration
      • 7.5.5.5.3. Market size and forecast, by Distribution Channels

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Novartis AG
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
  • 9.2. Merck and Co. Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
  • 9.3. Eli Lilly and Company
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
  • 9.4. Bristol-Myers Squibb Co.
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
  • 9.5. Teva Pharmaceutical Industries Ltd.
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
  • 9.6. Impax Laboratories Inc.
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
  • 9.7. Pfizer Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
  • 9.8. UCB SA
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
  • 9.9. Sun Pharmaceutical Industries Ltd.
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
  • 9.10. Mylan Nv
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot

LIST OF TABLES

  • TABLE 01. GLOBAL LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 02. LEVODOPA MARKET FOR TABLETS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. LEVODOPA MARKET FOR CAPSULES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. LEVODOPA MARKET FOR POWDER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. LEVODOPA MARKET FOR LIQUID, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. GLOBAL LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 07. LEVODOPA MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. LEVODOPA MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 10. LEVODOPA MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. LEVODOPA MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. LEVODOPA MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. LEVODOPA MARKET FOR OTHER , BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. LEVODOPA MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA LEVODOPA MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 19. U.S. LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 20. U.S. LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 21. U.S. LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 22. CANADA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 23. CANADA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 24. CANADA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE LEVODOPA MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 35. UK LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 36. UK LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 37. UK LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 41. SPAIN LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 44. ITALY LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 45. ITALY LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 46. ITALY LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC LEVODOPA MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 54. CHINA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 55. CHINA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 56. CHINA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 59. JAPAN LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 60. INDIA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 61. INDIA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 62. INDIA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 63. SOUTH KOREA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH KOREA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 66. AUSTRALIA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 67. AUSTRALIA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 68. AUSTRALIA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 75. LAMEA LEVODOPA MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 81. SAUDI ARABIA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 82. UNITED ARAB EMIRATES LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 83. UNITED ARAB EMIRATES LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 84. UNITED ARAB EMIRATES LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH AFRICA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH AFRICA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH AFRICA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 88. REST OF LAMEA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 89. REST OF LAMEA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 90. REST OF LAMEA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 91. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 92. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 93. MERCK AND CO. INC.: KEY EXECUTIVES
  • TABLE 94. MERCK AND CO. INC.: COMPANY SNAPSHOT
  • TABLE 95. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 96. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 97. BRISTOL-MYERS SQUIBB CO.: KEY EXECUTIVES
  • TABLE 98. BRISTOL-MYERS SQUIBB CO.: COMPANY SNAPSHOT
  • TABLE 99. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 100. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 101. IMPAX LABORATORIES INC.: KEY EXECUTIVES
  • TABLE 102. IMPAX LABORATORIES INC.: COMPANY SNAPSHOT
  • TABLE 103. PFIZER INC.: KEY EXECUTIVES
  • TABLE 104. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 105. UCB SA: KEY EXECUTIVES
  • TABLE 106. UCB SA: COMPANY SNAPSHOT
  • TABLE 107. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 108. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 109. MYLAN NV: KEY EXECUTIVES
  • TABLE 110. MYLAN NV: COMPANY SNAPSHOT

LIST OF FIGURES

  • FIGURE 01. LEVODOPA MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF LEVODOPA MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN LEVODOPA MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN LEVODOPA MARKET (2023-2032)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL LEVODOPA MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. IMPACT OF KEY REGULATION: LEVODOPA MARKET
  • FIGURE 12. PATENT ANALYSIS BY COMPANY
  • FIGURE 13. PATENT ANALYSIS BY COUNTRY
  • FIGURE 14. LEVODOPA MARKET, BY FORM, 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR TABLETS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR CAPSULES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR POWDER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR LIQUID, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR PARENTERAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR OTHER , BY COUNTRY 2022 AND 2032(%)
  • FIGURE 27. LEVODOPA MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 28. U.S. LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. CANADA LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. MEXICO LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. GERMANY LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. UK LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. FRANCE LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SPAIN LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. ITALY LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. REST OF EUROPE LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. CHINA LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. JAPAN LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. INDIA LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH KOREA LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. AUSTRALIA LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. REST OF ASIA-PACIFIC LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. BRAZIL LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. SAUDI ARABIA LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. UNITED ARAB EMIRATES LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. SOUTH AFRICA LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. REST OF LAMEA LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 49. COMPETITIVE DASHBOARD
  • FIGURE 50. COMPETITIVE HEATMAP: LEVODOPA MARKET
  • FIGURE 51. TOP PLAYER POSITIONING, 2022